SEARCH

SEARCH BY CITATION

References

  • 1
    Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193226.
  • 2
    Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55: 11522.
  • 3
    Williams C, Shattuck-Brandt RL, DuBois RN. The role of COX-2 in intestinal cancer. Ann N Y Acad Sci 1999; 889: 7283.
  • 4
    Farrow DC, Vaughan TL, Hansten PD et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97102.
  • 5
    Giovannucci E, Egan KM, Hunter DJ et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 60914.
  • 6
    Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 120.
  • 7
    Thun MJ. Aspirin, NSAIDs, and digestive tract cancers. Cancer Metastasis Rev 1994; 13: 26977.
  • 8
    Ensor CM, Tai HH. 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal 1995; 12: 3139.
  • 9
    Backlund MG, Mann JR, Holla VR et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005; 280: 321723.
  • 10
    Wolf I, O’Kelly J, Rubinek T et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006; 66: 781823.
  • 11
    Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM, Feldman D. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr 2007; 137: 205S10S.
  • 12
    Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005; 26: 6572.
  • 13
    Quidville V, Segond N, Lausson S, Frenkian M, Cohen R, Jullienne A. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins Other Lipid Mediat 2006; 81: 1430.
  • 14
    Myung SJ, Rerko RM, Yan M et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006; 103: 12098102.
  • 15
    Liu Z, Wang X, Lu Y et al. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 2008; 29: 121927.
  • 16
    Yoo NJ, Jeong EG, Lee SH. Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas. Pathology 2007; 39: 1745.
  • 17
    Jang TJ, Ji YS, Jung KH. Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas. Yonsei Med J 2008; 49: 91722.
  • 18
    Thiel A, Ganesan A, Mrena J et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res 2009; 15: 457280.
  • 19
    Watanabe T, Higuchi K, Kobata A et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008; 57: 1817.
  • 20
    Spyratos F, Ferrero-Pous M, Trassard M et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 2002; 94: 21519.
  • 21
    Tanigawa T, Watanabe T, Hamaguchi M et al. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2. Am J Physiol Gastrointest Liver Physiol 2004; 286: G14856.
  • 22
    Tanigawa T, Pai R, Arakawa T, Tarnawski AS. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci 2007; 52: 2407.
  • 23
    Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994; 35: 6758.
  • 24
    Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 51823.
  • 25
    Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002; 62: 4038.
  • 26
    Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65: 421827.
  • 27
    Mann JR, Backlund MG, Buchanan FG et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 2006; 66: 664956.
  • 28
    Yang L, Amann JM, Kikuchi T et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 2007; 67: 558793.
  • 29
    Saukkonen K, Rintahaka J, Sivula A et al. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003; 111: 91525.
  • 30
    Chen CN, Sung CT, Lin MT, Lee PH, Chang KJ. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg 2001; 233: 1838.
  • 31
    Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 2002; 66: 2229.
  • 32
    Lee TL, Leung WK, Lau JY et al. Inverse association between cyclooxygenase-2 overexpression and microsatellite instability in gastric cancer. Cancer Lett 2001; 168: 13340.
  • 33
    Leung WK, To KF, Ng YP et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001; 84: 3359.
  • 34
    Lim HY, Joo HJ, Choi JH et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 51925.
  • 35
    Murata H, Kawano S, Tsuji S et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 4515.
  • 36
    Okano H, Shinohara H, Miyamoto A, Takaori K, Tanigawa N. Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome. Clin Cancer Res 2004; 10: 693845.
  • 37
    Sung JJ, Leung WK, Go MY et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000; 157: 72935.
  • 38
    Chen L, Li X, Wang GL, Wang Y, Zhu YY, Zhu J. Clinicopathological significance of overexpression of TSPAN1, Ki67 and CD34 in gastric carcinoma. Tumori 2008; 94: 5318.
  • 39
    Fernandez-Cebrian JM, Nevado Santos M, Vorwald Kuborn P et al. Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression? Clin Transl Oncol 2007; 9: 66370.
  • 40
    Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6: 3948.
  • 41
    Ishida H, Miwa H, Tatsuta M et al. Ki67 and CEA expression as prognostic markers in Dukes’ C colorectal cancer. Cancer Lett 2004; 207: 10915.
  • 42
    Ito Y, Matsuura N, Sakon M et al. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 74751.
  • 43
    Skalova A, Lehtonen H, Von Boguslawsky K, Leivo I. Prognostic significance of cell proliferation in mucoepidermoid carcinomas of the salivary gland: clinicopathological study using MIB 1 antibody in paraffin sections. Hum Pathol 1994; 25: 92935.
  • 44
    Muller W, Schneiders A, Meier S, Hommel G, Gabbert HE. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996; 74: 75965.
  • 45
    Wakimoto N, Wolf I, Yin D et al. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 2008; 68: 697886.